Core Viewpoint - Sarepta Therapeutics, Inc. has faced significant stock price decline following the reported deaths of patients in clinical trials for its gene therapy drug ELEVIDYS, leading to a securities class action lawsuit from investors [1][4][10]. Group 1: Company Developments - On July 18, 2025, Sarepta's shares closed down $7.89, a decrease of 36%, after the announcement of a third patient death related to its experimental gene therapy [1]. - The lawsuit focuses on Sarepta's disclosures regarding the safety and efficacy of ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [4]. - The FDA has placed Sarepta's investigational gene therapy clinical trials for limb-girdle muscular dystrophy on clinical hold due to the reported patient deaths [10]. Group 2: Legal Actions - A securities class action lawsuit has been filed, representing investors who acquired Sarepta securities between June 22, 2023, and June 24, 2025 [2]. - The lawsuit alleges that Sarepta made false and misleading statements about the safety of ELEVIDYS and failed to disclose critical information regarding patient deaths [5][6]. - Hagens Berman, the law firm investigating the case, is urging affected investors to report their losses and is looking for individuals with knowledge to assist in the investigation [3][11]. Group 3: Regulatory and Market Impact - Following the patient deaths, Sarepta halted recruitment and dosing in some ELEVIDYS clinical studies, which has attracted regulatory scrutiny [7][8]. - The severity of adverse events related to ELEVIDYS has raised concerns about the therapy's current and future approval prospects [8]. - H.C. Wainwright has reduced its price target for Sarepta to $0, reflecting the negative market sentiment following these developments [10].

Group 1 - China Biopharmaceutical (1177.HK) saw a rise of over 3% after announcing a successful licensing agreement with Merck for its PD-1/VEGF dual antibody, expecting a $300 million milestone payment soon [1] - CSPC Pharmaceutical Group (1093.HK) increased by over 5% following the announcement of an exclusive licensing agreement with Madrigal Pharmaceuticals for the global development of its GLP-1 receptor agonist SYH2086 [1] - Youzan (8083.HK) surged over 7% as it projected a revenue of approximately 709 to 719 million RMB for the first half of the year, a year-on-year increase of about 3.3% to 4.8%, and a net profit of 68 to 74 million RMB, marking a turnaround from a loss last year [1] Group 2 - Xingsheng International (6058.HK) rose nearly 18% after the bank announced its commitment to embrace technological transformation and explore stablecoins and AI initiatives [2] - New Oriental Education (9901.HK) fell nearly 4% after reporting a 9.4% year-on-year increase in net revenue to $1.243 billion for the fourth quarter of fiscal year 2025, but a 73.7% drop in net profit [2] - Kingdee International (0268.HK) saw a rise of over 7% as it announced a board meeting to review its interim results and potential dividend distribution [2] Group 3 - Macau gaming stocks rose, with MGM China (2282.HK) up over 4% after Macquarie raised its forecast for Macau's total gaming revenue for 2025 by 5% to 235.7 billion RMB, indicating a year-on-year growth of 4% [3] - Gold stocks in Hong Kong continued to decline, with Tongguan Gold (0340.HK) dropping over 9% for six consecutive days, as spot gold prices fell below $3,270 per ounce [4] - Kangfang Biopharma (9926.HK) rose nearly 5% after announcing the completion of the first patient dosing in a pivotal clinical trial for its PD-1/VEGF dual-specific antibody [4] Group 4 - Weishi Jiajie (0856.HK) increased by over 3% as a report indicated that its Southeast Asia business is expected to see a significant revenue increase of 74% in 2024, with net profit contributing about 51% [5] Group 5 - Meta (META.US) exceeded revenue expectations and provided strong guidance for the current quarter, leading to an after-hours increase of over 11% [6] - Microsoft (MSFT.US) reported an 18% year-on-year growth in revenue, driven by its cloud business, with Azure revenue up 34% for the full year, resulting in an after-hours increase of over 8% [6] - Wingstop (WING.US) surged by 26.85% after reporting adjusted earnings per share of $1.00 for the second quarter, exceeding analyst expectations [6] Group 6 - Several biopharmaceutical stocks surged, with Replimune (REPL.US) up 101.33% following news of regulatory changes at the FDA that may ease pressure on gene therapy and vaccine companies [7] - Marvell Technology (MRVL.US) rose 7.07% after announcing a partnership with Rebellions to provide AI systems for regional projects in Asia-Pacific and the Middle East [7] - Palo Alto Networks (PANW.US) fell 5.58% after agreeing to acquire CyberArk Software for approximately $25 billion [8]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Sarepta Therapeutics, Inc. securities between June 22, 2023, and June 24, 2025, of the upcoming lead plaintiff deadline on August 25, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Sarepta securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 25, 2025 [3]. - The lawsuit claims that Sarepta made false and misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements since 2013 [4].

Core Viewpoint - Sarepta Therapeutics, Inc. experienced a significant decline in share price following the report of a third patient death related to its experimental gene therapy drug, ELEVIDYS, leading to a 36% drop in stock value on July 18, 2025 [1]. Group 1: Company Developments - The company reported the death of a third patient treated with ELEVIDYS, resulting in shares closing down $7.89 [1]. - A securities class action lawsuit has been filed against Sarepta, representing investors who acquired securities between June 22, 2023, and June 24, 2025 [2]. - The lawsuit focuses on Sarepta's disclosures regarding the safety and efficacy of ELEVIDYS, alleging that the company misled investors about the therapy's safety and potential for broader application [4]. Group 2: Legal and Regulatory Issues - The lawsuit claims that Sarepta made false statements and failed to disclose critical information, particularly regarding patient safety updates that began on March 18, 2025 [5]. - Following the initial death report, Sarepta halted recruitment and dosing in some clinical studies as requested by EU authorities [6]. - Subsequent deaths of patients treated with ELEVIDYS led to further regulatory scrutiny, including a safety communication from the FDA regarding acute liver failure risks [8]. Group 3: Market Reactions and Analyst Opinions - The financial press reported that following the lawsuit, H.C. Wainwright reduced its price target for Sarepta to $0, reflecting a loss of confidence in the company's future prospects [10]. - The investigation by Hagens Berman is focused on whether Sarepta misled investors about the safety and revenue potential of its gene therapies [11].

周三，部分生物制药公司股价飙升，截至发稿，Replimune(REPL.US)飙升逾85%， Sarepta Therapeutics (SRPT.US)上涨超16%， Capricor Therapeutics(CAPR.US)大涨超18%。消息面上，美国FDA生物制品评 估与研究中心主任普拉萨德在上任不到三个月后离职，正值FDA对多款基因疗法和疫苗采取严格监管措 施，引发市场关注。分析人士指出，他的离任可能有助于缓解监管压力，被视为基因疗法和疫苗企业的 利好消息。 ...

智通财经APP获悉，周三，部分生物制药公司股价飙升，截至发稿，Replimune(REPL.US)飙升逾85%， Sarepta Therapeutics (SRPT.US)上涨超16%，Capricor Therapeutics(CAPR.US)大涨超18%。消息面上，美 国FDA生物制品评估与研究中心主任普拉萨德在上任不到三个月后离职，正值FDA对多款基因疗法和疫 苗采取严格监管措施，引发市场关注。分析人士指出，他的离任可能有助于缓解监管压力，被视为基因 疗法和疫苗企业的利好消息。 ...

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

Last week, Sarepta voluntarily and temporarily paused all U.S. shipments of Elevidys. Elevidys had received traditional approval in June 2024 for ambulatory Duchenne muscular dystrophy (DMD) patients aged four years and older with a confirmed DMD gene mutation. Previously, in June 2023, it secured accelerated, conditional approval for non-ambulatory DMD patients. As gene therapies continue to evolve as a promising frontier in medical treatment, regulatory scrutiny intensifies following safety concerns. Rece ...

Sarepta Soars After FDA Says Some Patients Can Get Elevidys. Hear about the winners and losers on Wall Street with the Bloomberg Stock Movers report. https://t.co/CnwR9un0jS ...

近日，美国食品药品管理局（FDA）调查结果显示，一名八岁男童的死亡事故与Sarepta的基因疗法"无 关"。 （文章来源：华尔街见闻） 罗氏制药将恢复在美国市场之外的基因疗法Elevidys发货工作。 ...